Tolfenamic Acid

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Tolfenamic Acid
Accession Number
DB09216
Type
Small Molecule
Groups
Approved
Description

Tolfenamic acid is a member of the anthranilic acid derivatives (or fenamate) class of NSAID drugs discovered by scientists at Medica Pharmaceutical Company in Finland. Like other members of the class, it is a COX inhibitor and prevents formation of prostaglandins. It is used in the UK as a treatment for migraine. It is generally not available in the US. It is available in some Asian, Latin American and European countries as a generic drug for humans and for animals.

Structure
Thumb
Synonyms
Not Available
International/Other Brands
Clotam
Categories
UNII
3G943U18KM
CAS number
13710-19-5
Weight
Average: 261.704
Monoisotopic: 261.05565634
Chemical Formula
C14H12ClNO2
InChI Key
YEZNLOUZAIOMLT-UHFFFAOYSA-N
InChI
InChI=1S/C14H12ClNO2/c1-9-11(15)6-4-8-12(9)16-13-7-3-2-5-10(13)14(17)18/h2-8,16H,1H3,(H,17,18)
IUPAC Name
2-[(3-chloro-2-methylphenyl)amino]benzoic acid
SMILES
CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O

Pharmacology

Indication

For the treatment of migraine.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with 19-norandrostenedione.Experimental, Illicit
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Tolfenamic Acid.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Tolfenamic Acid.Vet Approved
5-androstenedioneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with 5-androstenedione.Experimental, Illicit
AbciximabTolfenamic Acid may increase the anticoagulant activities of Abciximab.Approved
AcebutololTolfenamic Acid may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Tolfenamic Acid.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolTolfenamic Acid may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tolfenamic Acid.Approved, Vet Approved
AclarubicinTolfenamic Acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Tolfenamic Acid.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Aldosterone.Experimental, Investigational
AldoxorubicinTolfenamic Acid may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Alendronic acid.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Tolfenamic Acid.Approved, Investigational
AliskirenTolfenamic Acid may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Alminoprofen.Experimental
AlprenololTolfenamic Acid may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Amcinonide.Approved
AmikacinTolfenamic Acid may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideTolfenamic Acid may decrease the antihypertensive activities of Amiloride.Approved
AmobarbitalThe metabolism of Tolfenamic Acid can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Tolfenamic Acid.Approved, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tolfenamic Acid.Approved, Investigational
AmrubicinTolfenamic Acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodTolfenamic Acid may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Tolfenamic Acid.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with anecortave acetate.Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Tolfenamic Acid.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Anisodamine.Investigational
AnnamycinTolfenamic Acid may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Tolfenamic Acid.Approved
Antithrombin III humanTolfenamic Acid may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanTolfenamic Acid may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Apocynin.Investigational
ApramycinTolfenamic Acid may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Tolfenamic Acid.Approved, Investigational
ArbekacinTolfenamic Acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinTolfenamic Acid may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanTolfenamic Acid may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Tolfenamic Acid.Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Tolfenamic Acid.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Atamestane.Investigational
AtenololTolfenamic Acid may decrease the antihypertensive activities of Atenolol.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Atosiban.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tolfenamic Acid.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tolfenamic Acid.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tolfenamic Acid.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Tolfenamic Acid.Experimental
BalsalazideTolfenamic Acid may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BarbexacloneThe metabolism of Tolfenamic Acid can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Tolfenamic Acid can be increased when combined with Barbital.Illicit
BecaplerminTolfenamic Acid may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololTolfenamic Acid may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinTolfenamic Acid may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Tolfenamic Acid.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tolfenamic Acid.Approved
BenorilateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Tolfenamic Acid.Withdrawn
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Tolfenamic Acid.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tolfenamic Acid.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Betamethasone.Approved, Vet Approved
BetaxololTolfenamic Acid may decrease the antihypertensive activities of Betaxolol.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Tolfenamic Acid.Approved, Investigational
BevantololTolfenamic Acid may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Bevonium.Experimental
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Tolfenamic Acid.Approved, Investigational
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
BisoprololTolfenamic Acid may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinTolfenamic Acid may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololTolfenamic Acid may decrease the antihypertensive activities of Bopindolol.Approved
Brefeldin AThe risk or severity of adverse effects can be increased when Brefeldin A is combined with Tolfenamic Acid.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tolfenamic Acid.Approved
BucillamineThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Bucillamine.Investigational
BucindololBucindolol may increase the hypotensive activities of Tolfenamic Acid.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Bufexamac.Experimental
BufuralolTolfenamic Acid may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Bumadizone.Experimental
BumetanideTolfenamic Acid may decrease the diuretic activities of Bumetanide.Approved
BunazosinBunazosin may increase the hypotensive activities of Tolfenamic Acid.Investigational
BupranololTolfenamic Acid may decrease the antihypertensive activities of Bupranolol.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Tolfenamic Acid.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Tolfenamic Acid.Approved
Calcium AcetateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium Carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium laevulate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium Phosphate.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Tolfenamic Acid.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Tolfenamic Acid.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Tolfenamic Acid.Withdrawn
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Tolfenamic Acid.Experimental
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Tolfenamic Acid.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Tolfenamic Acid.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Carbaspirin calcium.Experimental, Investigational
CarbomycinThe metabolism of Tolfenamic Acid can be decreased when combined with Carbomycin.Vet Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Tolfenamic Acid.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Tolfenamic Acid.Approved, Vet Approved, Withdrawn
CarteololTolfenamic Acid may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Tolfenamic Acid.Approved, Investigational
CaseinThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Tolfenamic Acid.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Tolfenamic Acid.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Tolfenamic Acid.Approved, Investigational
CeliprololTolfenamic Acid may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CerivastatinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Cerivastatin.Withdrawn
CertoparinTolfenamic Acid may increase the anticoagulant activities of Certoparin.Approved, Investigational
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Tolfenamic Acid.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Tolfenamic Acid.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tolfenamic Acid.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Tolfenamic Acid.Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tolfenamic Acid.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Tolfenamic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Tolfenamic Acid.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Ciclesonide.Approved, Investigational
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Tolfenamic Acid.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tolfenamic Acid.Approved
CimetidineThe serum concentration of Tolfenamic Acid can be increased when it is combined with Cimetidine.Approved
CinoxacinTolfenamic Acid may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidTolfenamic Acid may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Tolfenamic Acid can be decreased when combined with Clarithromycin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Clonixin.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Tolfenamic Acid.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Tolfenamic Acid.Vet Approved
CloranololTolfenamic Acid may decrease the antihypertensive activities of Cloranolol.Experimental
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Tolfenamic Acid.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Tolfenamic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Tolfenamic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Tolfenamic Acid.Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Tolfenamic Acid.Experimental
CyclosporineTolfenamic Acid may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateTolfenamic Acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinTolfenamic Acid may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidTolfenamic Acid may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Tolfenamic Acid.Investigational
DarexabanTolfenamic Acid may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinTolfenamic Acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Tolfenamic Acid.Experimental
DesirudinTolfenamic Acid may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Tolfenamic Acid.Approved, Investigational
DextranTolfenamic Acid may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Tolfenamic Acid may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Tolfenamic Acid may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Tolfenamic Acid may increase the anticoagulant activities of Dextran 75.Approved
DibekacinTolfenamic Acid may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Tolfenamic Acid.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tolfenamic Acid.Approved, Vet Approved
DicoumarolTolfenamic Acid may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tolfenamic Acid.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Tolfenamic Acid.Approved
DihydrostreptomycinTolfenamic Acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Tolfenamic Acid.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Tolfenamic Acid.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Tolfenamic Acid.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Tolfenamic Acid.Approved
DoxorubicinTolfenamic Acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneTolfenamic Acid may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Tolfenamic Acid.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with E-6201.Investigational
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Tolfenamic Acid.Approved
Edetic AcidTolfenamic Acid may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanTolfenamic Acid may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe serum concentration of Tolfenamic Acid can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Tolfenamic Acid.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Tolfenamic Acid.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tolfenamic Acid.Approved
EnoxacinTolfenamic Acid may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinTolfenamic Acid may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Tolfenamic Acid.Experimental
EpanololTolfenamic Acid may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Tolfenamic Acid.Approved
EpirubicinTolfenamic Acid may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneTolfenamic Acid may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tolfenamic Acid.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tolfenamic Acid.Approved
EquileninThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Equilin.Approved
ErythromycinThe metabolism of Tolfenamic Acid can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmololTolfenamic Acid may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Estrone sulfate.Approved
Etacrynic acidTolfenamic Acid may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Tolfenamic Acid.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Ethenzamide.Experimental
Ethyl biscoumacetateTolfenamic Acid may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Tolfenamic Acid.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Tolfenamic Acid.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Tolfenamic Acid.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Evening primrose oil.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Tolfenamic Acid.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Tolfenamic Acid.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Tolfenamic Acid.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Tolfenamic Acid.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Tolfenamic Acid.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fentiazac.Experimental
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Tolfenamic Acid.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Feprazone.Experimental
Ferulic acidTolfenamic Acid may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tolfenamic Acid.Approved, Investigational
FleroxacinTolfenamic Acid may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Tolfenamic Acid.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluasterone.Investigational
FluconazoleThe serum concentration of Tolfenamic Acid can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Tolfenamic Acid.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fludrocortisone.Approved
FluindioneTolfenamic Acid may increase the anticoagulant activities of Fluindione.Investigational
FlumequineTolfenamic Acid may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Tolfenamic Acid.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tolfenamic Acid.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluticasone propionate.Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Tolfenamic Acid.Experimental
FluvastatinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluvastatin.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tolfenamic Acid.Approved, Nutraceutical, Vet Approved
FondaparinuxTolfenamic Acid may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumTolfenamic Acid may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Tolfenamic Acid.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tolfenamic Acid.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Tolfenamic Acid.Approved
FramycetinTolfenamic Acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideTolfenamic Acid may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateTolfenamic Acid may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinTolfenamic Acid may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinTolfenamic Acid may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Tolfenamic Acid.Approved, Withdrawn
GemifloxacinTolfenamic Acid may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinTolfenamic Acid may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinTolfenamic Acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ATolfenamic Acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Tolfenamic Acid.Experimental
GPX-150Tolfenamic Acid may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinTolfenamic Acid may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Tolfenamic Acid.Approved, Vet Approved
GuacetisalThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Guacetisal.Experimental
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Tolfenamic Acid.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Haloperidol.Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Tolfenamic Acid.Approved, Withdrawn
HE3286The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with HE3286.Investigational
HeparinTolfenamic Acid may increase the anticoagulant activities of Heparin.Approved, Investigational
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Tolfenamic Acid.Approved, Investigational
HexobarbitalThe metabolism of Tolfenamic Acid can be increased when combined with Hexobarbital.Approved
HigenamineThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Higenamine.Investigational
HydralazineTolfenamic Acid may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tolfenamic Acid.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
Hygromycin BTolfenamic Acid may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tolfenamic Acid.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Tolfenamic Acid.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Tolfenamic Acid.Approved
IdarubicinTolfenamic Acid may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxTolfenamic Acid may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Tolfenamic Acid.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tolfenamic Acid.Approved
IndenololTolfenamic Acid may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tolfenamic Acid.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Tolfenamic Acid.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Tolfenamic Acid.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tolfenamic Acid.Approved, Investigational
IsepamicinTolfenamic Acid may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Tolfenamic Acid.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Tolfenamic Acid.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Istaroxime.Investigational
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Tolfenamic Acid.Approved, Investigational
JosamycinThe metabolism of Tolfenamic Acid can be decreased when combined with Josamycin.Approved, Investigational
KanamycinTolfenamic Acid may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Tolfenamic Acid.Experimental
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Tolfenamic Acid.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Tolfenamic Acid.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tolfenamic Acid.Approved
KitasamycinThe metabolism of Tolfenamic Acid can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Tolfenamic Acid.Approved
LandiololTolfenamic Acid may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Tolfenamic Acid.Approved, Investigational
LepirudinTolfenamic Acid may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanTolfenamic Acid may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololTolfenamic Acid may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinTolfenamic Acid may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Tolfenamic Acid.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Tolfenamic Acid.Approved
LonazolacThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Tolfenamic Acid.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Tolfenamic Acid.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Loteprednol.Approved
LovastatinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Tolfenamic Acid.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Tolfenamic Acid.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Tolfenamic Acid.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tolfenamic Acid.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tolfenamic Acid.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tolfenamic Acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tolfenamic Acid.Approved
MelagatranTolfenamic Acid may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tolfenamic Acid.Approved, Vet Approved
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Tolfenamic Acid.Experimental
MepindololTolfenamic Acid may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineTolfenamic Acid may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Tolfenamic Acid.Investigational, Withdrawn
MethohexitalThe metabolism of Tolfenamic Acid can be increased when combined with Methohexital.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Tolfenamic Acid.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tolfenamic Acid.Approved
MethylphenobarbitalThe metabolism of Tolfenamic Acid can be increased when combined with Methylphenobarbital.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Methylprednisolone.Approved, Vet Approved
MetipranololTolfenamic Acid may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tolfenamic Acid.Approved
MetoprololTolfenamic Acid may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideTolfenamic Acid may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Tolfenamic Acid.Experimental
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Tolfenamic Acid.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Tolfenamic Acid.Approved, Investigational, Vet Approved
MicronomicinTolfenamic Acid may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Tolfenamic Acid.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tolfenamic Acid.Approved
MizoribineThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Tolfenamic Acid.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Mometasone.Approved, Vet Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Tolfenamic Acid.Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tolfenamic Acid.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tolfenamic Acid.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tolfenamic Acid.Approved
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Tolfenamic Acid.Experimental
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Tolfenamic Acid.Approved
NadololTolfenamic Acid may decrease the antihypertensive activities of Nadolol.Approved
NadroparinTolfenamic Acid may increase the anticoagulant activities of Nadroparin.Approved
NafamostatTolfenamic Acid may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NafcillinThe metabolism of Tolfenamic Acid can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Tolfenamic Acid.Approved
Nalidixic AcidTolfenamic Acid may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Tolfenamic Acid.Approved, Vet Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Tolfenamic Acid.Approved
NCX 1022The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with NCX 1022.Investigational
NeamineTolfenamic Acid may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololTolfenamic Acid may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinTolfenamic Acid may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinTolfenamic Acid may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tolfenamic Acid.Approved
NetilmicinTolfenamic Acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tolfenamic Acid.Approved
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Tolfenamic Acid.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Tolfenamic Acid.Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tolfenamic Acid.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Nitroaspirin.Investigational
NitroprussideTolfenamic Acid may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Tolfenamic Acid.Approved
NorfloxacinTolfenamic Acid may increase the neuroexcitatory activities of Norfloxacin.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Tolfenamic Acid.Approved, Vet Approved
OleandomycinThe metabolism of Tolfenamic Acid can be decreased when combined with Oleandomycin.Vet Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tolfenamic Acid.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tolfenamic Acid.Approved
OlsalazineTolfenamic Acid may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of can be d when Tolfenamic Acid is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Tolfenamic Acid.Investigational
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Tolfenamic Acid.Experimental
OrgoteinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Orgotein.Vet Approved
OtamixabanTolfenamic Acid may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tolfenamic Acid.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Tolfenamic Acid.Approved
Oxolinic acidTolfenamic Acid may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololTolfenamic Acid may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tolfenamic Acid.Approved, Withdrawn
PafuramidineThe risk or severity of adverse effects can be increased when Pafuramidine is combined with Tolfenamic Acid.Investigational
PamidronateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Tolfenamic Acid.Approved
ParomomycinTolfenamic Acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Parthenolide.Investigational
PazufloxacinTolfenamic Acid may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinTolfenamic Acid may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololTolfenamic Acid may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateTolfenamic Acid may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Tolfenamic Acid.Approved
PentobarbitalThe metabolism of Tolfenamic Acid can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateTolfenamic Acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Tolfenamic Acid.Approved
PhenindioneTolfenamic Acid may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Tolfenamic Acid can be increased when combined with Phenobarbital.Approved
PhenprocoumonTolfenamic Acid may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tolfenamic Acid.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Tolfenamic Acid.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tolfenamic Acid.Approved, Investigational
PindololTolfenamic Acid may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidTolfenamic Acid may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinTolfenamic Acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideTolfenamic Acid may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tolfenamic Acid.Approved, Investigational
Piromidic acidTolfenamic Acid may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tolfenamic Acid.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Pirprofen.Experimental
PitavastatinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Pitavastatin.Approved
Platelet Activating FactorTolfenamic Acid may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinTolfenamic Acid may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinTolfenamic Acid may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tolfenamic Acid.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Tolfenamic Acid.Approved, Investigational, Vet Approved
PractololTolfenamic Acid may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Tolfenamic Acid.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Prasterone sulfate.Investigational
PravastatinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Pravastatin.Approved
PrazosinPrazosin may increase the hypotensive activities of Tolfenamic Acid.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Pregnenolone.Experimental, Investigational
PrimidoneThe metabolism of Tolfenamic Acid can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Tolfenamic Acid can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Propacetamol.Approved, Investigational
PropranololTolfenamic Acid may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Tolfenamic Acid.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Tolfenamic Acid.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Tolfenamic Acid.Vet Approved
Protein CTolfenamic Acid may increase the anticoagulant activities of Protein C.Approved
Protein S humanTolfenamic Acid may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeTolfenamic Acid may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinTolfenamic Acid may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Tolfenamic Acid.Investigational
PuromycinTolfenamic Acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Tolfenamic Acid.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Tolfenamic Acid.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tolfenamic Acid.Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Tolfenamic Acid.Experimental
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Tolfenamic Acid.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tolfenamic Acid.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tolfenamic Acid.Approved, Experimental, Investigational
ReviparinTolfenamic Acid may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinTolfenamic Acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RifabutinThe serum concentration of Tolfenamic Acid can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Tolfenamic Acid can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Tolfenamic Acid can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Tolfenamic Acid can be decreased when it is combined with Rifaximin.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Risedronate.Approved, Investigational
RivaroxabanTolfenamic Acid may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Tolfenamic Acid.Investigational, Withdrawn
RosoxacinTolfenamic Acid may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RosuvastatinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Rosuvastatin.Approved
RufloxacinTolfenamic Acid may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinTolfenamic Acid may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Tolfenamic Acid.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Tolfenamic Acid.Approved
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Tolfenamic Acid.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tolfenamic Acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Tolfenamic Acid.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tolfenamic Acid.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Tolfenamic Acid.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Tolfenamic Acid.Approved
SecobarbitalThe metabolism of Tolfenamic Acid can be increased when combined with Secobarbital.Approved, Vet Approved
SemapimodThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Tolfenamic Acid.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Serrapeptase.Investigational
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Tolfenamic Acid.Approved
SilodosinSilodosin may increase the hypotensive activities of Tolfenamic Acid.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Tolfenamic Acid.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Tolfenamic Acid.Approved, Investigational
SisomicinTolfenamic Acid may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinTolfenamic Acid may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Tolfenamic Acid.Approved
SolithromycinThe metabolism of Tolfenamic Acid can be decreased when combined with Solithromycin.Investigational
SotalolTolfenamic Acid may decrease the antihypertensive activities of Sotalol.Approved
SP1049CTolfenamic Acid may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinTolfenamic Acid may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinTolfenamic Acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Tolfenamic Acid.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Tolfenamic Acid.Investigational
StreptomycinTolfenamic Acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinTolfenamic Acid may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Tolfenamic Acid.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tolfenamic Acid.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Tolfenamic Acid.Approved
SulodexideTolfenamic Acid may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Tolfenamic Acid.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Tolfenamic Acid.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Suxibuzone.Experimental
TacrolimusTolfenamic Acid may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Tolfenamic Acid.Approved
TalinololTolfenamic Acid may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Tolfenamic Acid.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Tolfenamic Acid.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Tolfenamic Acid.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Tolfenamic Acid.Approved
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Tolfenamic Acid.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Technetium Tc-99m medronate.Approved
TelithromycinThe metabolism of Tolfenamic Acid can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tolfenamic Acid.Approved, Investigational
TemafloxacinTolfenamic Acid may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Tolfenamic Acid.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tolfenamic Acid.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Tepoxalin.Vet Approved
TerazosinTerazosin may increase the hypotensive activities of Tolfenamic Acid.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Tolfenamic Acid.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Tolfenamic Acid.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Tolfenamic Acid.Approved
TertatololTolfenamic Acid may decrease the antihypertensive activities of Tertatolol.Experimental
ThiamylalThe metabolism of Tolfenamic Acid can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Tolfenamic Acid can be increased when combined with Thiopental.Approved, Vet Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Tolfenamic Acid.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Tolfenamic Acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololTolfenamic Acid may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Tinoridine.Investigational
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Tolfenamic Acid.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Tixocortol.Approved, Withdrawn
TobramycinTolfenamic Acid may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Tolfenamic Acid.Experimental
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tolfenamic Acid.Approved
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Tolfenamic Acid.Approved, Vet Approved
TorasemideTolfenamic Acid may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Tolfenamic Acid.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Tolfenamic Acid.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tolfenamic Acid.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tolfenamic Acid.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Triamcinolone.Approved, Vet Approved
TriamtereneTolfenamic Acid may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tolfenamic Acid.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Tolfenamic Acid.Experimental
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Tolfenamic Acid.Approved, Investigational
TriptolideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Triptolide.Investigational
TrovafloxacinTolfenamic Acid may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinTolfenamic Acid may increase the anticoagulant activities of Troxerutin.Investigational
TylosinThe metabolism of Tolfenamic Acid can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Ubidecarenone.Approved, Investigational, Nutraceutical
UlobetasolThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Tolfenamic Acid.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Tolfenamic Acid.Investigational, Withdrawn
ValrubicinTolfenamic Acid may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Tolfenamic Acid.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Tolfenamic Acid.Approved
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Tolfenamic Acid.Approved, Investigational
WarfarinTolfenamic Acid may increase the anticoagulant activities of Warfarin.Approved
XimelagatranTolfenamic Acid may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tolfenamic Acid.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Tolfenamic Acid.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Tolfenamic Acid.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tolfenamic Acid.Withdrawn
Zoptarelin doxorubicinTolfenamic Acid may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinTolfenamic Acid may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
  1. Pentikainen PJ, Neuvonen PJ, Backman C: Human pharmacokinetics of tolfenamic acid, a new anti-inflammatory agent. Eur J Clin Pharmacol. 1981;19(5):359-65. [PubMed:7238564]
External Links
Human Metabolome Database
HMDB42043
KEGG Drug
D01183
PubChem Compound
610479
PubChem Substance
310265123
ChemSpider
530683
BindingDB
35905
ChEBI
32243
ChEMBL
CHEMBL121626
PharmGKB
PA166049189
HET
TLF
Wikipedia
Tolfenamic_acid
ATC Codes
M01AG02 — Tolfenamic acid
PDB Entries
4g77 / 5ikt

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0158 mg/mLALOGPS
logP4.64ALOGPS
logP5.49ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)3.88ChemAxon
pKa (Strongest Basic)-2.1ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area49.33 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity71.65 m3·mol-1ChemAxon
Polarizability26.46 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-1290000000-90928e5629bf0b4869e8
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a59-2790000000-175a0f838779d665e3db

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Aminobenzoic acids
Alternative Parents
Benzoic acids / Aminotoluenes / Aniline and substituted anilines / Benzoyl derivatives / Chlorobenzenes / Aryl chlorides / Vinylogous amides / Amino acids / Secondary amines / Monocarboxylic acids and derivatives
show 6 more
Substituents
Aminobenzoic acid / Benzoic acid / Benzoyl / Aniline or substituted anilines / Aminotoluene / Chlorobenzene / Halobenzene / Toluene / Aryl chloride / Aryl halide
show 18 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
organochlorine compound, secondary amino compound, aminobenzoic acid (CHEBI:32243)

Drug created on October 21, 2015 10:21 / Updated on November 09, 2017 04:47